Pfizer culls three phase 1 projects

Pfizer's second-quarter pipeline update disclosed the discontinuations of PF-07265807, PF-07209960 and PF-07209326. PF-07265807, an AXL/MER inhibitor, had entered the clinic in 2020 and was being evaluated in a first-in-human trial in selected advanced solid tumours. The first-in-human study of PF-07209960 (IL-15 activator) in solid tumours had been initiated in late 2020, and an earlier update posted on clinicaltrials.gov stated that it was terminated owing to a business decision "not based on safety or regulatory considerations". Meanwhile, the phase 1 trial of PF-07209326 (anti-E-selectin antibody) in healthy volunteers and sickle cell disease patients had kicked-off in early 2020.